New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls. Read the Q3 2026 report

Pfizer Inc.

PFE

Healthcare Drug Manufacturers General

Pfizer Inc.’s revenue for fiscal 2025 (year ended December 2025) was $62.6 billion, down 1.65% from fiscal 2024.

Revenue
−0.43%
EPS
−9.68%
Free cash flow
+20.0%
Total debt
+1.55%

Quarter to September 2026, against a year earlier

27.60 0.03 +0.11%
Market cap
$158.2B
P/E
38.8×
Fwd P/E FY26e
18.7×
Dividend yield
6.24%
F-score
6/9
ROIC
6.19%
Net debt / EBITDA
2.5×
Payout ratio
2.5×

Pfizer Inc. 10-Q filed Nov 3, 2026

Fiscal Q3 2026 · Period ended Sep 27, 2026 · Filed · accepted 8:19 AM ET · Document on sec.gov · Filing index

What changed

Part II, Item 1A, Risk Factors, against the 10-Q filed Aug 4, 2026: no comparison — incorporated by reference